1. WHO Expert Committee on Specifications for Pharmaceutical Preparations, Annex 10, Stability testing of active pharmaceutical ingredients and finished pharmaceutical products, WHO Technical Report Series, No. 1010, 2018. [cited 2021 April 23]. https://apps.who.int/iris/bitstream/handle/10665/272452/9789241210195-eng.pdf.
2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Stability testing of new drug substances and products, Q1A(R2), 2003. [cited 2021 April 23]. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf.
3. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Pharmaceutical Development, Q8(R2), 2009. [cited 2021 April 23]. https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf.
4. The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP), Note for guidance on in-use stability testing of human medicinal products, CPMP/QWP/2934/99, 2001. [cited 2021 April 23]. https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-use-stability-testing-human-medicinal-products_en.pdf.
5. The European Agency for the Evaluation of Medicinal Products, Committee for Veterinary Medicinal Products, Note for guidance on in-use stability testing of veterinary medicinal products (excluding immunological veterinary medicinal products), EMEA/CVMP/424/01-Final, 2002. [cited 2021 April 23]. https://www.ema.europa.eu/en/documents/scientific-guideline/note-guidance-use-stability-testing-veterinary-medicinal-products-excluding-immunological-veterinary_en.pdf.